Natural Capsules Ltd
Incorporated in 1993, Natural Capsules manufactures Capsules and Steroidal APIs and their Intermediates and Derivatives[1]
- Market Cap ₹ 196 Cr.
- Current Price ₹ 190
- High / Low ₹ 299 / 164
- Stock P/E 20.3
- Book Value ₹ 167
- Dividend Yield 0.00 %
- ROCE 7.39 %
- ROE 4.50 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.14 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 8.85% over last 3 years.
- Contingent liabilities of Rs.70.8 Cr.
- Dividend payout has been low at 1.61% of profits over last 3 years
- Promoter holding has decreased over last 3 years: -5.30%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59 | 67 | 62 | 54 | 55 | 60 | 62 | 80 | 135 | 171 | 153 | 168 | 177 | |
| 47 | 56 | 52 | 49 | 49 | 55 | 56 | 68 | 109 | 135 | 132 | 148 | 156 | |
| Operating Profit | 11 | 12 | 10 | 5 | 6 | 5 | 5 | 11 | 26 | 36 | 21 | 19 | 20 |
| OPM % | 19% | 17% | 16% | 10% | 10% | 8% | 9% | 14% | 19% | 21% | 14% | 12% | 11% |
| 1 | 1 | 1 | 0 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 4 | 6 | |
| Interest | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 4 | 5 | 6 | 6 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 7 | 9 | 8 | 8 |
| Profit before tax | 7 | 8 | 6 | 0 | 2 | 2 | 1 | 9 | 19 | 26 | 10 | 9 | 13 |
| Tax % | 39% | 25% | 28% | -103% | 34% | 7% | 38% | 24% | 28% | 25% | 25% | 28% | |
| 5 | 6 | 4 | 1 | 1 | 2 | 1 | 7 | 14 | 19 | 8 | 7 | 10 | |
| EPS in Rs | 6.08 | 7.15 | 4.99 | 0.68 | 1.19 | 2.06 | 0.92 | 7.47 | 15.00 | 20.83 | 8.38 | 6.49 | 9.34 |
| Dividend Payout % | 17% | 14% | 20% | 99% | 56% | 32% | 43% | 9% | 5% | 5% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 22% |
| 3 Years: | 7% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 51% |
| 3 Years: | -22% |
| TTM: | 67% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 24% |
| 3 Years: | -28% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 10% |
| 3 Years: | 9% |
| Last Year: | 5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 9 | 9 | 10 | 10 |
| Reserves | 38 | 42 | 50 | 48 | 48 | 49 | 49 | 56 | 76 | 115 | 123 | 156 | 162 |
| 6 | 5 | 6 | 3 | 0 | 5 | 6 | 10 | 33 | 49 | 62 | 56 | 59 | |
| 11 | 11 | 16 | 14 | 19 | 14 | 14 | 26 | 28 | 38 | 37 | 45 | 54 | |
| Total Liabilities | 59 | 63 | 77 | 71 | 73 | 75 | 76 | 98 | 144 | 211 | 231 | 268 | 286 |
| 31 | 29 | 30 | 26 | 22 | 24 | 24 | 35 | 63 | 93 | 91 | 88 | 90 | |
| CWIP | 2 | 2 | 0 | 0 | 1 | 2 | 2 | 3 | 1 | 0 | 2 | 0 | 0 |
| Investments | 0 | 0 | 5 | 5 | 5 | 5 | 6 | 0 | 0 | 20 | 23 | 23 | 23 |
| 26 | 32 | 42 | 40 | 45 | 43 | 45 | 60 | 80 | 98 | 116 | 157 | 172 | |
| Total Assets | 59 | 63 | 77 | 71 | 73 | 75 | 76 | 98 | 144 | 211 | 231 | 268 | 286 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | 5 | 3 | 2 | 5 | 2 | 7 | 6 | 5 | 20 | 5 | 18 | |
| -4 | -4 | -8 | -0 | -1 | -7 | -6 | -9 | -30 | -55 | -11 | -34 | |
| -3 | -1 | 4 | -2 | -4 | 4 | -1 | 3 | 27 | 34 | 7 | 15 | |
| Net Cash Flow | 0 | -0 | 0 | 0 | 0 | -1 | 0 | -0 | 1 | -1 | 2 | -2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 118 | 125 | 167 | 191 | 208 | 197 | 180 | 123 | 71 | 111 | 128 | 133 |
| Inventory Days | 53 | 66 | 147 | 119 | 149 | 87 | 89 | 82 | 34 | 43 | 83 | 92 |
| Days Payable | 70 | 74 | 148 | 159 | 185 | 114 | 91 | 157 | 97 | 127 | 140 | 155 |
| Cash Conversion Cycle | 101 | 117 | 166 | 151 | 172 | 170 | 179 | 48 | 7 | 28 | 70 | 70 |
| Working Capital Days | 103 | 87 | 123 | 155 | 186 | 136 | 121 | 114 | 32 | 28 | 30 | 40 |
| ROCE % | 18% | 17% | 12% | 3% | 4% | 5% | 4% | 11% | 23% | 20% | 8% | 7% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Dec
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
19 Nov - Q2 revenue Rs45.80cr, net loss Rs6.99cr; FY26 guidance trimmed to ~Rs225cr; API ramp-up issues, US tariff impact.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
17 Nov - Audio recording of investor conference call on November 17, 2025 posted on company website.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Newspaper Publication regarding Unaudited Standalone & Consolidated Financial Results for the Quarter and half year ended September 30,2025
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
14 Nov - Q2 revenue ₹45.80Cr, PAT loss ₹6.99Cr; H1 revenue ₹91.01Cr, PAT loss ₹12.57Cr; tariffs, API delays.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2025Transcript PPT
-
Aug 2025TranscriptAI SummaryPPT
-
Jun 2025TranscriptPPT
-
Jun 2025Transcript PPT REC
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024Transcript PPT REC
-
May 2024Transcript PPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptPPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptAI SummaryPPT
-
Jun 2023Transcript PPT
-
Feb 2023TranscriptAI SummaryPPT
-
Oct 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
Business Overview:[1][2][3]
NCL is a WHO-GMP certified and ISO 9001, ISO 140001 compliance manufacturer of printed and unprinted hard two-piece Gelatin and Cellulose (HPMC : non-animal alternative) capsules for pharmaceutical and dietary supplement industries in various sizes of 00, 0el, 0, 1, 2, 3 & 4. Apart from this, NCL has forayed into API manufacturing with complex high-end patented technology developed in-house, under its subsidiary company Natural Biogenex Private Limited.